drugset
drugset / Trial / NCT00795769

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

NCT00795769 ↗

Phase 2 Completed 49 enrolled Fred Hutchinson Cancer Center
NaSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients undergoing stem cell transplant.

Timeline

Start
2008-08-08
Primary completion
2009-06-09
Completion
2009-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified — Intravenous

Indications

Burkitt lymphoma Hodgkins lymphoma MALT lymphoma acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, t(16;16)(p13.1;q22) acute promyelocytic leukemia adult acute lymphoblastic leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic eosinophilic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma chronic myelomonocytic leukemia chronic neutrophilic leukemia diffuse large B-cell lymphoma female breast carcinoma gestational trophoblastic neoplasm hairy cell leukemia large-cell immunoblastic lymphoma leukemia, myeloid, accelerated-phase malignant testicular germ cell tumor mantle cell lymphoma mycosis fungoides and variants myelodysplastic syndrome myeloproliferative neoplasm, unclassifiable neuroblastoma nodal marginal zone B-cell lymphoma ovarian carcinoma ovarian germ cell tumor plasma cell myeloma primary myelofibrosis splenic marginal zone lymphoma